NEW YORK (CBSNewYork) – Pancreatic cancer patients now have a new treatment option.
The Food and Drug Administration approved the use of Lynparza for patients with tumors that didn’t grow after 16 weeks of chemotherapy.READ MORE: Heavy Rain Has Queens Residents Worried About Ida Repeat: 'I'm Scared To Death'
The drug is currently used to treat ovarian and breast cancer.READ MORE: New Jersey Under State Of Emergency As Nor'easter Threatens Flood Prone Areas
Pancreatic cancer is the third largest cause of death from cancer and is often not detected until late stages.
“Patients with advanced pancreatic cancer historically have faced poor outcomes due to the aggressive nature of the disease and limited treatment advances over the last few decades. Lynparza is now the only approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer,” Dave Fredrickson, the executive vice president of the oncology business unit of drugmaker AstraZeneca said in a statement.MORE NEWS: Storm Watch: Timeline Of Rare October Nor'easter Soaking Tri-State Area
The drug is already approved to treat ovarian and breast cancer.